This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Vitreous and retina, Subject name: Ophthalmology
[{'content': 'Which of the following agents is not used in the treatment of Diabetic Macular Edema Retinopathy- \nSelect and explain. \nA. Ruboxistaurim, B. Pyridazinones, C. Benfotiamine, D. Tamoxifen', 'role': 'user'}, {'content': 'Answer: D \nExplanation: Antivascular endothelial growth factor (anti-VEGF) Vascular endothelial growth factor (VEGF) plays a pivotal role in the etiopathogenesis of diabetic maculopathy and retinopathy. Anti-VEGFs when given intravitrealy in 0.1 ml vehicle lead to improvement in vision in > 40% cases and stabilise vision in another >40% cases. They include : Ranibizumab (Lucentis) Pegaptanib ( Macugen) Bevacizumab (Avastin) Ref; A.K.Khurana; 6th edition; Page no: 281,459', 'role': 'assistant'}]